Meridian to acquire recombinant proteins from Vybion

The purchase price includes cash and future royalties based on net sales of the acquired products, the amounts of which were not disclosed. The assets to be acquired include a portfolio of recombinant viral proteins and cardiac antigens, customer lists, supply agreements, patent and technology rights, equipment, and on-hand inventory. These products will be manufactured at Meridian’s wholly owned subsidiary, Meridian Life Science located in Memphis.

The products to be acquired from Vybion add to the growing portfolio of highly specialized biologicals that Meridian manufactures and distributes to the diagnostic, pharmaceutical, and research markets. This acquisition adds important technologies and capabilities to Meridian’s Life Science business and is said to complement Meridian’s expanding life science brands: Biodesign, OEM Concepts, Viral Antigens, and Meridian Biologics.

Completion of the transaction is subject to execution of a definitive purchase agreement, satisfactory due diligence, and other customary conditions. The transaction is expected to be completed during the next 30 to 60 days.